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Background
Germline mutations in the DNA mismatch repair genes
MLH1 and MSH2 are associated with substantially
increased risks of colorectal cancer (CRC), endometrial
cancer (EC) and certain other cancers. Due to the rarity
of these mutations, previous studies have been under-
powered to provide precise estimates of risks.
Methods
We studied 167 MLH1 and 225 MSH2 mutation-carry-
ing families comprising 17,352 members from the Colon
Cancer Family Registry. Probands were recruited either
because they had a family history of cancer (n=274) or
from cancer registries independently of family history
(n=118). Hazard ratios (HRs) of cancer risks for carriers
compared with the general population and age-specific
cumulative risks for carriers (penetrance) were estimated
using modified segregation analysis conditioned on
ascertainment. Heterogeneity in risks for carriers was
modelled with a polygenic risk modifier (as in the BOA-
DICEA model).
Results
The age-specific incidence of CRC for male MLH1
mutation carriers was estimated to be 222 times (95%
CI: 152-324) that for the population at ages 40 years
and younger but only 6.1 times higher (95% CI: 2.4-
15.5) after age 60 years. This decline (p<0.0001) in the
CRC HR with age was also evident for female MLH1
mutation carriers (p=0.002) but was less marked. Male
MLH1 mutation carriers on average had higher CRC
HRs than female carriers (p=0.004). The estimated CRC
HRs for MSH2 mutation carriers were similar to those
for MLH1, with any differences consistent with chance
(p>0.3). The estimated EC HRs also decreased sharply
with age (p=0.0004 and 0.001 for MLH1 and MSH2,
respectively) and no difference by gene was observed
(p=0.7). There was strong evidence for an unmeasured
polygenic modifier of risk (p<0.0001). The estimated
average cumulative risks (95% CI) of CRC to age 70
years were 44% (35-54) for male carriers and 38% (30-
48) for female carriers, and corresponding EC risks were
22% (14-31). However for carriers in the lowest vs. high-
est quartiles of polygenic risk (respectively) these were
4.9% vs. 93% for male CRC, 3.5% vs. 88% for female
CRC and 1.5% vs. 59% for EC.
Conclusions
This international study shows that, although the aver-
age cancer risks for MLH1 and MSH2 mutation carriers
are similar, there is substantial unexplained variation in
risks due to differences by mutation or by genetic or
environmental modifiers. This finding has implications
for the counselling and clinical management of mutation
carriers.
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